By my count, Vumerity is the 18th disease-modifying therapy (DMT) that the U.S. Food and Drug Administration (FDA) has approved for multiple sclerosis (MS). It’s one of very few approved for secondary progressive MS (SPMS). I find it hard to understand why more DMTs haven’t been approved for progressive forms of our disease. Is it because applying for FDA approval costs pharmaceutical companies more than the profit they expect to make from medications for primary and secondary progressive forms of MS? Bravo to the neuros who are prescribing high-efficiency meds, such as Lemtrada (alemtuzumab), for people with progressive forms even when they haven’t been approved for that use.
In a news release, Biogen said that it intends to make Vumerity available in the U.S. “in the near future.”
The U.S. Food and Drug Administration (FDA) has approved Vumerity (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive disease (SPMS).
Click here to read the rest of the story.
The big takeaway from this report is not included in the headline, so I’ve written my own: “Low Levels of Infection-fighting Antibodies Found in Blood of People with MS, but Appear to Be Unrelated to Disease-modifying Therapy Use.” As someone who’s been treated with various DMTS for decades, I feel more comfortable after learning that information.
People with multiple sclerosis (MS) tend to have low levels in their blood serum of certain antibodies that can protect against infection, regardless of whether they are using a disease-targeted therapy or not, a study reports.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?